Edwards Lifesciences Corp.EW

Health Care · Health Care Equipment & Services · NYSE · United States · edwards.com

Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease and critical care, headquartered in Irvine, California. The company develops, manufactures, and markets transcatheter heart valve replacement products under the SAPIEN family, transcatheter mitral and tricuspid therapies under the PASCAL and EVOQUE brands, and surgical heart valve solutions under the INSPIRIS brand. Edwards Lifesciences serves customers in the United States, Europe, Japan, and internationally with approximately 16,000 employees.

Key ratios

Operating cash flow growth

116.4%TTM

2025 194.2%2024 -39.5%2023 -26.5%

EPS growth

-29.9%TTM

2025 -22.7%2024 16.4%2023 -5.2%

FCF / Sales

22.0%TTM

2025 22.0%2024 5.3%2023 12.8%

Net margin

15.4%TTM

2025 17.7%2024 76.8%2023 28.0%

ROA

7.7%TTM

2025 7.7%2024 8.3%2023 10.5%

ROE

10.4%TTM

2025 10.4%2024 16.6%2023 19.5%

Revenue growth

14.6%TTM

2025 11.6%2024 8.6%2023 12.2%

Recent news

Edwards' Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves 2026-06-26 · Business Wire CMS proposes Medicare coverage expansion for TAVR 2026-06-16 · Healthcare Dive

Track EW in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer